RSS

tumour

The US FDA has expanded its approval of Imfinzi (durvalumab) to now include the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumours are unresectable and have not progressed after chemoradiation treatment. more

News

A new strategy to tackle the issue of long-term treatment efficacy in cancer patients has been developed by researchers from the Netherlands Cancer Institute in collaboration with international biotechnology company, Genmab. more

News

Nanobiotix, a late clinical-stage nanomedicine company, has started a pre-clinical collaboration with the Providence Cancer Institute to study NBTXR3 — a nanoparticle designed for direct injection into cancerous tumours and activation by radiotherapy more

News

Cancer researchers are excited by new work that is indicating a cheap, over-the-counter cold remedy (N-Acetyl cysteine, or NAC) can inhibitor the tumour stroma — a cell compartment that is fundamental to the spread of cancer. more

News

A research team from the Netherlands Cancer Institute has discovered the underlying mechanism to why cancer cells become addicted to the drugs that are administered to kill them, which may lead to more rational alternating therapies. more

News

The high-pressure environment of pancreatic cancer tumours are behind most drugs failing, according to researchers from the Fred Hutchinson Cancer Research Center more

News

BioCellChallenge has announced its positive results from in-vivo tests of a therapeutic antibody more

News

A minimally invasive vaccine that combines cancer cells and immune-enhancing factors promises to “launch a destructive attack” on tumors more

News

Findings presented at the EORTC, EANO and ESMO congress in Istanbul demonstrate that EDO-S101 is effective in models of human glioblastoma irrespective of methyltransferase status and in combination with radiotherapy. more

News

At the same time, Recipharm Venture Fund has invested SEK 8 million in Isofol Medical. more

This immunotherapy is designed to induce a robust immune response against Brachyury, a tumour-associated antigen which is overexpressed in every major solid tumour setting more